NCT01498952View on ClinicalTrials.gov

MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

January 17, 2012

Primary Completion Date

April 9, 2013

Study Completion Date

April 9, 2013

Conditions
Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Interventions
DRUG

MEDI-573 (1 of 3 doses)

MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands

DRUG

Sorafenib

Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor

Trial Locations (3)

80401

Research Site, Golden Springs

89169

Research Site, Las Vegas

93030

Research Site, Oxnard

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY